A recent study published in the Annals of Internal Medicine has revealed a significant increase in the number of individuals without diabetes being prescribed GLP-1 drugs, while new prescriptions for those with diabetes have seen a decline. This trend raises concerns about potential shortages of these treatments, which are critical for those diagnosed with type 2 diabetes.
GLP-1 medications, known for mimicking a hormone that manages blood sugar levels and appetite, were originally marketed for type 2 diabetes management. However, the FDA’s approval of Wegovy for weight loss in 2021 has shifted the focus to non-diabetic patients seeking weight-loss solutions.
Researchers analyzed medical records from 45 million Americans between 2011 and 2023, discovering that the percentage of new GLP-1 users with type 2 diabetes dropped from nearly 90% to over 70%. Conversely, the share of new users without diabetes rose from 10% to 25%. Yee Hui Yeo, a co-author of the study, noted the transition in healthcare providers’ perspectives on the benefits of these medications for obesity treatment, emphasizing a noteworthy change in public health approach.
This increasing demand has impacted production capabilities for both Novo Nordisk and Eli Lilly, as they struggle to meet the needs of the expanding user base. Despite the soaring interest and resultant sales that have propelled these companies to significant market value, the urgency for increased supply also underscores the importance of ensuring that patients with diabetes still have access to these essential drugs.
Morgan Stanley projects the global market for GLP-1 drugs could reach a staggering $105 billion by 2030, anticipating that about 31.5 million Americans—nearly 9% of the population—will be using these medications by 2035.
This shift in medication usage not only highlights the growing recognition of obesity as a critical health issue but also signals a need for healthcare systems to adapt and ensure fair access to treatments for all individuals, particularly those who rely on these medications for managing chronic conditions like diabetes. As the landscape of pharmaceutical treatments evolves, there is hope that solutions will emerge to meet the demands of both diabetic and non-diabetic patients effectively.